Keywords: |
review; cisplatin; doxorubicin; fluorouracil; interferon; antineoplastic agents; alpha interferon; paclitaxel; methotrexate; topotecan; alpha2b interferon; bcg vaccine; carboplatin; bone marrow suppression; granulocyte macrophage colony stimulating factor; camptothecin; cyclophosphamide; dose-response relationship, drug; bladder cancer; ifosfamide; vinblastine; docetaxel; irinotecan; folinic acid; carcinoma in situ; epirubicin; mitomycin c; neoplasm invasiveness; bladder neoplasms; isotretinoin; carcinoma, transitional cell; granulocyte colony stimulating factor; clinical trials; genetic markers; trimetrexate; piritrexim; edatrexate; gallium nitrate; human; support, u.s. gov't, p.h.s.
|